ABG-WTT Global Life Science Capital Partners GP Ltd Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001832108
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2024 · 4 positions · Total reported value $43.71M · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 50.0% · 0 new · 0 cut · 1 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
In its Q4 2024 13F filing, ABG-WTT Global Life Science Capital Partners GP Ltd disclosed 4 equity positions with a combined reported value of $43.71M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q4 2024 were CBLL ($28.16M), CGON ($14.21M), RPID ($934.47K). By sector, the heaviest allocations are Health Care 97.9%, Industrials 2.1%. Versus the prior quarter, allocation shifted toward Health Care (+2.5pp) and away from Industrials (-2.5pp).
Versus the prior quarter, ABG-WTT Global Life Science Capital Partners GP Ltd opened 0 new positions, trimmed 0 and fully exited 1, a turnover rate of 50.0% of positions. The portfolio's overlap with the prior quarter was 75% of names.
The largest new positions opened in Q4 2024 were CBLL ($28.16M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2024)
- CBLL CERIBELL INC · $28.16M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest ABG-WTT Global Life Science Capital Partners GP Ltd buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
ABG-WTT Global Life Science Capital Partners GP Ltd is an SEC-registered 13F filer. As of Q3 2026 it reported 1 US equity positions with a combined value of $1.90M. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Portfolio Structure
- 1 positions · $1.90M reported value (Q3 2026)
- Top 10 holdings = 100.0% of reported value
- Largest position: RPID (RAPID MICRO BIOSYSTEMS INC) at 100.0%
- Average position size: $1.90M
Sector Tilt
- Industrials 100.0%
- (classified holdings cover 100% of value)
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
FAQ
What did ABG-WTT Global Life Science Capital Partners GP Ltd buy in 2024-Q4?
In its 2024-Q4 13F filing, ABG-WTT Global Life Science Capital Partners GP Ltd reported 4 equity positions worth $43.71M in aggregate; its largest disclosed positions were CBLL ($28.16M), CGON ($14.21M), RPID ($934.47K).
How large is ABG-WTT Global Life Science Capital Partners GP Ltd's portfolio?
ABG-WTT Global Life Science Capital Partners GP Ltd reported $43.71M of long equity holdings across 4 positions as of 2024-Q4. Top-10 holdings account for 100.0% of reported value.
What is ABG-WTT Global Life Science Capital Partners GP Ltd's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.